Among the claims, NeuMoDx has alleged that BD was kept up to date on the firm's technology as it was developed and that one of the patents was duplicitously expanded by BD.
Qiagen's Q2 revenues of $381.6 million represented 5 percent year-over-year growth at constant exchange rates, but came in just under the Wall Street estimate.
UK researchers said they are developing a commercial test that could enable sensitive detection of tuberculosis DNA in blood and provide an option to broaden screening.
Evercore noted that while Qiagen is on target to hit previously issued 2020 financial targets, its recently issued long-term guidance for 2023 is less of a sure thing.
McKesson will be the exclusive distributor of the QiaStat-Dx system in US hospitals with fewer than 200 beds and non-exclusive distributor for future expansion into retail pharmacy clinics.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.
